[en] The identification of relevant clinical outcomes of sarcopenia could be helpful for health professionals to improve sarcopenia management and for designing valid and useful clinical trials and outcome studies. Through observational studies, a flow of outcomes associated with sarcopenia has already been identified.1–4 However, to ensure that the outcomes measured reflect those that matter most to patients, incorporation of the patients' perspective in clinical research is also critical.5,6 Qualitative interviews with experts and patients are a wise way to generate original outcomes not usually observed in studies designed with large cohorts of patients.
Disciplines :
Public health, health care sciences & services General & internal medicine
Author, co-author :
Beaudart, Charlotte ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Cruz-Jentoft, A.J.
Vaquero-Pinto, M.N.
Locquet, Médéa ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie clinique
Bauer, J.
Cooper, C.
Rolland, Y.
Dupuy, C.
Landi, F.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Visser, M., Schaap, L.A., Consequences of sarcopenia. Clin Geriatr Med 27 (2011), 387–399.
Beaudart, C., Zaaria, M., Pasleau, F., et al. Health outcomes of sarcopenia: A systematic review and meta-analysis. PLoS One, 12, 2017, e0169548.
Janssen, I., Shepard, D.S., Katzmarzyk, P.T., Roubenoff, R., The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc 52 (2004), 80–85.
Bruyère, O., Beaudart, C., Ethgen, O., et al. The health economics burden of sarcopenia: A systematic review. Maturitas 119 (2019), 61–69.
de Wit, M., Cooper, C., Tugwell, P., et al. Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: Results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res 31 (2019), 905–915.
Caldwell, B., Value and use of patient-reported outcomes (PROs) in assessing effects of medical devices. Available at: https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/default.ht, 2016. (Accessed 10 May 2019)
Hiligsmann, M., Beaudart, C., Bruyère, O., et al. Outcomes priorities for older persons with sarcopenia. J Am Med Dir Assoc, 2019 [In Press].
Lancsar, E., Louviere, J., Conducting discrete choice experiments to inform healthcare decision making. Pharmacoeconomics 26 (2008), 661–677.
Ryan, M., Bate, A., Eastmond, C.J., Ludbrook, A., Use of discrete choice experiments to elicit preferences. Qual Health Care 10 (2001), i55–i60.
Ryan, M., Gerard, K., Using discrete choice experiments to value health care programmes: Current practice and future research reflections. Appl Health Econ Health Policy 2 (2003), 55–64.
